No way this trial takes a year to enroll! It’s only 60 patients; look at it from their standpoint, they are being offered standard of care, not denied the best treatment option, PLUS Leronlimab with no serious safety signal to give them pause and the push to sign the informed consent form is the very real prospect it could move the needle on their MSS CRC who’s median survival will otherwise put them in a casket in 12 months…it’s a no brainer. The offer of palpable hope at negligible decision cost should lead to fairly quick enrollment.